Overview

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Oncozyme Pharma Inc.

Treatments:

Pentamidine